šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lycia Therapeutics, Inc. (LYCA)
NASDAQ: LYCA Ā· Real-Time Price Ā· USD
33.07
+1.30 (4.09%)
At close: Nov 20, 2026, 4:00 PM EST
33.30
+0.23 (0.70%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

The platform’s three Phase I programs target IgE-mediated disease and Graves’ disease. Initial 70 mg LCA-0061 data showed 96% mean maximum reductions in total and free IgE; further program data are planned for 2027.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Good afternoon. Good afternoon, everyone. Thank you for joining. Welcome to the Jefferies Global Healthcare Conference here in London. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. We are really pleased to have with us today the management team of Lycia Therapeutics. CEO Aetna Wun Trombley is here with us and is going to give us a rundown of the Lycia story.

Aetna Wun Trombley
CEO, Lycia Therapeutics

Thank you, Faisal. Appreciate the opportunity to present for the first time actually as a public company since our IPO three weeks ago, and happy to share the story today. All right. Lycia's foundational technology came from Carolyn Bertozzi's lab at Stanford, and it is geared towards driving extracellular proteins by co-opting the lysosome, and which is why our platform is called Lysosomal Targeting Chimera, or LYTACs. We have really advanced the platform over the last few years to what we believe is a differentiated modality, largely due to our cataLYTACs, which means that it can drive catalytic degradation of target. We also have made it quite a modular platform, such that now we have three programs that we are advancing to phase I proof of concept. We have LCA-0061 and LCA-0062, both cataLYTACs degrading IgE for food allergy and other allergic diseases. We also have LCA-0321.

This is a selective degrader of the TSHR autoantibodies that drive Graves' disease. All of these are large multi-billion dollar I&I markets. We recently reported, as part of our IPO, initial data from our ongoing LCA-0061 phase I study. We believe that this data supports the differentiation thesis of our IgE cataLYTACs, but also serves as initial proof of mechanism for our platform. Happy to share that with you later today. All right. I just want to share a couple slides describing our platform. The first is really describing our foundational technology of LYTACs and classic LYTACs, which means that they degrade targets in a one-to-one ratio. LYTACs are heterobifunctional molecules. One side binds the target that you are trying to degrade. The other side binds what we call internalizing receptors. It is shown here in purple.

Internalizing receptors naturally traffic from the cell surface to the lysosome, where proteins are ultimately degraded. As I mentioned, classic LYTACs degrade in a one-to-one ratio because LYTACs in this format are degraded in the lysosome along with the target. These are well-suited for those targets that are in low circulating concentrations and importantly have slow resynthesis rates. A perfect example of that are autoantibodies, which is why LCA-0321 is a classic LYTAC. However, there are many, many targets that we actually would like to target that drive disease that are in much higher concentrations in patients and are more rapidly resynthesized. That is why it is really critical to design what we call cataLYTACs, such that for every molecule of drug, you can degrade at least 40 target molecules.

That is the key differentiating feature and actually only makes IgE possible as a really differentiated profile because of the cataLYTACs. We will better describe that with NHP and clinical data from our LCA-0061 program. As important for any modality and new technology, I think it is really important to think through what you apply it to. We have decided to work on targets that are very well validated and known to drive a particular disease. We have initially focused in large I&I markets. Importantly, at the start of the program, we really want to have a strong differentiation hypothesis as to why degrading a target is going to be differentiated from other approaches, like blockers.

Then we generate NHP data, or non-human primate data, comparing our cataLYTACs or LYTACs from a very relevant clinical comparator. Then very quickly try to translate those findings in a phase I proof of concept study in patients, if possible. As you see, the pipeline programs that we are going to talk about today that follow this, and you can think about also our future programs will follow this strategy as well. This is a summary of our pipeline. We are going to have a quick overview today of each of these programs. As I mentioned, we have two IgE cataLYTAC degraders, LCA-0061, which is in an ongoing phase I study where we reported out initial data, which we will review with you today. We have LCA-0062. This is a fast follow-on molecule.

We believe that this is such a high-value target, it was important for us to have the potential to have two products. This is less than a year behind LCA-0061, and we will talk more about what we are going to do with LCA-0061 and LCA-0062 in a little bit. Then we have LCA-0321 that is in an ongoing phase I study in Graves' disease patients. As you can see here, and we will close on this, we have a lot of catalysts coming up in the next 12, 24 months. First, I am going to turn to the IgE program for food allergy and other allergic diseases. I think I will just spend one slide to really summarize the significant opportunity that food allergy represents, with over 30 million patients in the U.S.

XOLAIR, which is an anti-IgE blocker, represents actually the first biologic to be approved for the treatment of food allergy, and that was approved in February of 2024. Roche has actually reported the quarterly launch numbers. If you actually plot XOLAIR's launch in food allergy and compare it to DUPIXENT's AD launch and SKYRIZI's psoriasis launch, the food allergy launch has actually outpaced both of these, and you know the significant size of these franchises. I think that having a best-in-class IgE-targeting therapeutic in food allergy can represent a very significant opportunity. Before I share our clinical data, I want to put IgE in the context of an allergy patient. We first start on the left panel. This is an allergy patient where we all have circulating IgE, which means IgE is available to bind to its main receptor, which is FcεRI.

These receptors are expressed on effector cells like basophils and mast cells. When you are sensitized to an allergen, shown here in orange, it can bind to these surface-bound IgE, and this cross-linking that happens on the surface of these cells is what ultimately drives a potential anaphylaxis response in a food allergy or an allergy patient. What happens when you dose XOLAIR or a blocker in the middle panel, shown in pink? What happens is when you dose a blocker, you actually increase the pool or reservoir of IgE, which consists of both bound IgE and free IgE, which means, again, you have an increased opportunity for IgE to be available and bind to its receptor as well as to allergen. While XOLAIR has provided some protection, we believe it is not complete protection, as best evidenced by its phase III food allergy study.

On the right panel is what we would like to achieve with an IgE cataLYTAC, where we achieve elimination of both total and free IgE. If you do that sufficiently, you should be able to see a downregulation of its main receptor, again, FcεRI, on effector cells. As you can see here depicted on the right, you do not have IgE around. You also have minimal receptor expression. When you come into contact with an allergen, there is more complete protection, right, in the sense that there is no instigation of an anaphylaxis response. What does that mean then in terms of data that you would like to see? On the left are the IgE blockers. This is a schematic, but it is backed up by data that you see here on the bottom.

What happens again with total IgE, omalizumab, and another blocker, ozureprubart, they drive, with a single dose, an elevation of total IgE, as I just described, and a transient reduction of free IgE that rebounds after a few days. Whereas the goal for an IgE cataLYTAC with a single dose would be to drive a very rapid, deep depletion of both total IgE and free IgE for as long as possible. As I described before, we wanted to demonstrate this hypothesis in NHPs, so we ran a single-dose experiment subq comparing omalizumab, shown in red, versus three dose levels of LCA-0061 in blue. If you look at the left, this is total IgE.

You can see in red, omalizumab, as I described, drives an elevation of total IgE relative to vehicle control in gray, whereas a single dose of LCA-0061 can drive reductions of total IgE to limits of detection for at least two weeks. On the right, free IgE. Again, omalizumab drives a transient reduction of free IgE, which rebounds after a few days, whereas a single dose of LCA-0061 drives a reduction, again, of free IgE to limits of detection for about two weeks. The ongoing phase I study where we wanted to translate the findings that I just shared with you in NHP into human. On the left is the single ascending dose where we are evaluating the drug versus placebo, six on drug versus two placebo, in atopic healthy participants, which means that they have elevated serum IgE of at least 300 IU/ mL.

We completed cohort A1, which was the 70 mg subq dose, and that is the data that I am going to share with you today. We are currently in cohort A2, where we went threefold up in dose at 210 mg. The main objectives were to assess safety and tolerability, but of course, we are going to measure total and free IgE as well as PK. We will be moving into a multiple ascending dose where we will be evaluating, again, six on drug versus two placebo, but now we are going to require peanut allergy. We are also going to allow inclusion of other food allergens, and they will have elevated IgE. It is important that we wanted to evaluate this drug in food allergy patients so that we could collect really important PD markers shown here, including the skin prick test as well as the basophil activation test.

In totality, this data in the food allergy patients will really inform what doses we can take into a food allergy oral food challenge study. This is the summary of the baseline demographics from the first cohort. I want to point to the box here in blue, which really describes a little bit more of this atopic patient population that we evaluated. The mean baseline total IgE was close to 600 IU/ mL, which is relatively high, as normal IgE levels are in the order of 100 IU/ mL or less. We also wanted to assess if these were food allergy patients, what dose of omalizumab they would have received. We looked at the baseline body weight levels as well as their baseline IgE levels, and we determined that these patients would have been on the highest dose levels of omalizumab.

So 450 mg to 600 mg, as you know, is the highest doses of omalizumab, and some of the patients would have been dosed at those levels in this cohort. All of them have elevated, all these eight patients we evaluated have elevated IgE because they all have allergic rhinitis. Most of them have allergic conjunctivitis. We had one mild AD patient, and all of them tested positive on a skin prick test. Summary, blinded safety data through day 35 indicated that when all participants completed the study, we had no dose-limiting toxicities or any safety signals. We had two participants experiencing grade 1 mild treatment-related TEAEs. They both resolved without treatment. We are still blinded, so we do not know if it is on drug or placebo.

Consistent with the mechanism of action, as you may recall, we are rapidly internalizing the drug and driving it to the liver, and this is also our first low-dose cohort, so we do not have much by way of serum exposure. As we go up in dose, we should expect to increase. This is the total IgE data from our first cohort. On the left is mean actual total IgE levels, and on the right is the mean percent change versus baseline. The 70 mg single dose cohort drove a 96% mean max reduction. This happened very early, so you can see at the 24-hour time point, we already achieved a 92% mean reduction. This was nice to see that it was sustained through the treatment period, where the majority of patients actually were still greater than 95% reduced at day 28.

It's a pretty significant effect. You would expect free IgE to track, and it does. Also a single dose of LCA-0061 drove a 96% mean max reduction relative to baseline. Then, consistent with what I was describing earlier, if you drive down IgE levels sufficiently, you should also see a downregulation of the main receptor, FcεRI. We do see a sustained reduction of the receptor through the treatment period for the majority of patients. This is all very consistent with our hypothesis and mechanism of action, and we look forward to generating more data from our ongoing study. As I mentioned earlier, we have a fast follow-on molecule, LCA-0062. It's a fully biologic construct, so this is a bispecific antibody, where the initial intention was really just to streamline CMC.

We also evaluated it in a very similar NHP study where we had single dose, subq omalizumab in red versus single doses of LCA-0062 in blue. We see again very consistent activity with OMA driving an elevation of total IgE and a transient reduction of free IgE, whereas LCA-0062 drives a very sustained depletion of both total and free IgE for at least a month. You can see we have a nice durable depletion even more extended than LCA-0061. The intent of this program is to, or this molecule is to also move it into a phase I study and generate data to support the translation of this NHP study and then determine which molecule will move into a late-stage phase II oral food challenge study.

As you can appreciate, there are many diseases that are driven by IgE, and we'll use the clinical data to inform the other indications that we'll pursue with the molecules. I would now like to turn to, actually, one of the things that before I turn to the Graves' disease program is really to step back and talk about why we believe that IgE cataLYTACs have the potential to be best in class. XOLAIR is, as some of you may know, is dosed through a dosing table, which means that based on your body weight and your IgE levels, there actually may be a large, there is a large group of patients who are actually ineligible for XOLAIR. The highest IgE level you can be treated with XOLAIR is 1850 IU/ mL.

When we do an evaluation of how many patients are estimated to be ineligible for XOLAIR, that's 20%-30% of the food allergy population, and that's pretty significant. Important for us, right, because we're likely to be in a world where biosimilars will be available, which actually will be coming online as disclosed by Roche later this year. It's really important to have this differentiation both from an efficacy perspective, as well as in addition to any convenience, basically because we will be able to access patients that are going to be ineligible for XOLAIR or its biosimilar, and then having the potential to provide more complete protection for those patients that are within the dosing table. Now I'd like to turn to our next program, LCA-0321 for Graves' disease.

This is also another significant autoimmune condition where there is quite a bit of unmet need. This is about 3 million adults with Graves' disease in the U.S., largely affecting women. Actually, 2% of women have Graves' disease. Unfortunately, the only drug that is available are these very old antithyroid drugs, which only address the symptoms and not the drivers, which are the TSHR autoantibodies. Because you only address the symptoms, a large percentage, about 55%, actually do not achieve remission. If you are not responsive or not able to tolerate ATDs, your only option is to get surgical removal of your thyroid or get radioactive iodine, which are not preferred options.

We are aiming to develop a selective treatment for Graves' disease to either serve as second line to those that fail ATDs, but also have the potential to be first line for those that have to be surgical candidates. LCA-0321 is designed, as I mentioned earlier, to degrade only the TSHR autoantibodies. If you see here in red, it actually only makes up a small percentage of the overall concentration of IgG. We all have grams of IgG in circulation, and there is a much lower target burden if you are only selectively removing the TRAbs, which make up about 50 ng/mL to 500 ng/ mL.

It is going to be important both from an efficacy perspective, again, for the goal of the LYTAC is to knock down as much as possible only the pathogenic autoantibodies, keep the remaining IgG pool intact to ensure that you do not have any broader immunosuppressive risk in doing so. We also want to make sure that we have designed the molecule to not touch TSH, such that we do not induce the risk of any hypothyroidism. This is the study design of our ongoing phase I study of LCA-0321. On the left describes the single ascending dose. We are evaluating the effects of the drug, six on drug versus two placebo, in active Graves' disease patients. They are euthyroid but have elevated TRAbs. The goal for this study is to mainly assess, or this part of the study is to mainly assess safety and tolerability.

Of course, we are going to be measuring TSHR autoantibody levels to show the impact of the drug on the reductions of these levels. Then with sufficient safety data from the single ascending dose, we will move into a multiple ascending dose population, and then ideally, we would like to move into a hyperthyroid Graves' disease population, meaning they have elevated T3, T4 hormone marker levels, and we would like to demonstrate the ability to reduce both the TRAbs and then correlatively reductions in T3 and T4. In summary, this is the catalyst that we will have from all of our programs next year. Again, from our LCA-0061, our IgE cataLYTAC molecule will report out additional data from the ongoing phase I study in 2027. For LCA-0062, this is our fast follow-on biologic bispecific antibody.

We will initiate the phase I study and report out initial data in the second half of next year. For our Graves' disease program that I just described, LCA-0321, we will report out initial data in 2027. Just to keep everyone on your toes, we also have another program that we will disclose next year. What I will say is that this is very similar in our thesis that I described earlier, which is to go after validated targets that are known to drive diseases, in this case, multiple immune-mediated diseases. We have a very strong hypothesis for differentiation of why you need to degrade this target versus other approaches, including blocking approaches. We demonstrate that in NHP head-to-head against a very relevant clinical comparator to demonstrate that differentiation. Very quickly, the goal now is to move into phase I to translate that.

As mentioned, we just completed our IPO a few weeks ago that generated $365 million in gross proceeds. As you can imagine, if we were successful with all of these programs, the plan right now is to plan for success, and many of these could run, go into late-stage development. With that, I would like to thank you for your attention.